Candel Therapeutics Inc [CADL] stock is trading at $5.81, down -5.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CADL shares have gain 13.92% over the last week, with a monthly amount drifted -0.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup started tracking the stock with Buy rating on February 20, 2025, and set its price target to $25. On February 19, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $20 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $15 on February 07, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $11 as its price target on December 02, 2022. BMO Capital Markets started tracking with a Outperform rating for this stock on November 19, 2021, and assigned it a price target of $18. In a note dated August 23, 2021, UBS initiated an Buy rating and provided a target price of $9 on this stock.
Candel Therapeutics Inc [CADL] stock has fluctuated between $3.79 and $14.60 over the past year. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $5.81 at the most recent close of the market.
Analyzing the CADL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.37 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.69 points at the first support level, and at 5.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.03, and for the 2nd resistance point, it is at 6.24.
Ratios To Look Out For
For context, Candel Therapeutics Inc’s Current Ratio is 4.64. As well, the Quick Ratio is 4.64, while the Cash Ratio is 4.59.
Transactions by insiders
Recent insider trading involved Nichols William Garrett, Chief Medical Officer, that happened on Jun 30 ’25 when 781.0 shares were sold. Officer, WILLIAM GARRETT NICHOLS completed a deal on Jun 30 ’25 to buy 3593.0 shares. Meanwhile, Chief Medical Officer Nichols William Garrett sold 45316.0 shares on Mar 18 ’25.
